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Abstract
Background
In Uzbekistan, despite stable and relatively high tuberculosis treatment success rates, rela-
tively high rates of recurrent tuberculosis have recently been reported. Recurrent tuberculo-
sis is when a patient who was treated for pulmonary tuberculosis and cured, later develops
the disease again. This requires closer analysis to identify possible causes and recommend
interventions to improve the situation. Using countrywide data, this study aimed to analyse
trends in recurrent tuberculosis cases and describe their associations with socio-demo-
graphic and clinical factors.
Method
Countrywide retrospective cohort study comparing recurrent tuberculosis patients with all
new tuberculosis patients registered within the NTP between January 2006 and December
2010 using routinely collected data. Determinants studied were baseline characteristics and
treatment outcomes.
Results
Of 107,380 registered patients during the period January 2006 and December 2010, 9358
(8.7%) were recurrent cases. Between 2006 and 2008, the number of recurrent cases per
annum increased from 1530 to 2081, then fell slightly thereafter from 2081 to 1888 cases.
The proportion of all notified cases during this period increased from 6.5% to 9.9%. Factors
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associated with recurrent tuberculosis included age (35–55 years old), having smear posi-
tive pulmonary tuberculosis, residing in certain areas of Uzbekistan, having particular co-
morbidities (including chronic obstructive pulmonary disease and HIV), and being unem-
ployed, a pensioner or disabled. Recurrent tuberculosis patients also had a higher likelihood
of having an unfavourable treatment outcome
Conclusion
Despite signs of declining national tuberculosis notifications between 2006 and 2010, the
relative proportion of recurrent cases appears to have increased. These findings, together
with the identification of possible risk factors associated with recurrent tuberculosis, highlight
various areas where Uzbekistan needs to focus its tuberculosis control efforts, particularly in
light of the country’s rapidly emerging multi drug resistant tuberculosis epidemic.
Introduction
Despite major advances in tuberculosis (TB) control, TB is still one of the largest public health
challenges globally, and no less in Central Asia where TB incidence rates remain high [1]. The
Republic of Uzbekistan, one of the 15 former Republics of the Soviet Union, is the most popu-
lous country in Central Asia and had an estimated TB incidence of 82 per 100,000 population
in 2014 [1]. It is among the 18 high-priority countries for TB control in the WHO European
region and one of the 27 high burden countries for multidrug-resistant TB (MDR-TB) globally
[1].
Uzbekistan began a phased implementation of the WHO-recommended DOTS (directly
observed treatment, short-course) strategy in 1998 and by 2005, DOTS had been rolled out
countrywide, with case detection based mainly on passive case finding [2]. Over the last
decade, Uzbekistan has made commendable strides in its TB control efforts: country data
reported by the WHO indicate that the notification rate of new and recurrent TB cases
declined almost 32% between 2006 and 2010 (from 91 to 62 per 100 000 population) [3], and
treatment success rates have been stable and relatively high at around 83% (albeit just short of
the 85% target set by the WHO). However, TB recurrence rates in the country are relatively
high.
“Recurrent TB” patients are defined as patients who have previously been treated for TB,
were declared cured or treatment completed at the end of their most recent course of treat-
ment, and are now diagnosed with a recurrent episode of TB (either a true relapse due to reac-
tivation of the disease or a new episode of TB caused by reinfection) [4]. Recurrent TB is an
indicator of community control of TB and a proxy of TB drug-resistance. A study carried out
during 2001–2002 in Republic of Karakalpakstan—an autonomous republic of Uzbekistan—
showed that among 118 successfully treated TB patients, 36% were re-diagnosed with active
TB within the next 22 months, with 52% of these re-diagnoses being sputum smear-positive
for Acid Fast Bacilli (AFB). Patients classified as treatment completed had significantly higher
smear-positive recurrence than those classified as cured [5].
The findings from studies conducted in other countries have shown that risk factors for
recurrent TB include irregular drug intake, initial drug resistance, smoking, and alcoholism
[6,7].
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To date, there has been no analysis of country-wide data in Uzbekistan to describe the num-
ber and proportion of TB patients with recurrent disease or their trends over time. Moreover,
risk factors associated with recurrent TB at the national level have not been described or ana-
lyzed in detail. The national TB control programme (NTP) uses a centralised individual-
patient electronic database which allows for the detailed analysis of such data at a national
level. Information on recurrent TB cases will be useful for the national TB control programme
in Uzbekistan, and potentially other countries in the region, to consider interventions to
address these challenges.
Using countrywide TB data from Uzbekistan, this study aimed to describe trends and risk
factors for recurrent TB between 2006 and 2010. Specific objectives were to determine: i) the
trend of recurrent TB annually over a five year period between 2006 and 2010 and ii) the asso-
ciation of socio-demographic, clinical characteristics and co-morbidities of patients with
recurrent TB compared to those registered with new TB between 2006 and 2010.
Methods
Study design
This was a retrospective cohort study comparing recurrent TB patients with new TB patients
registered within the NTP between January 2006 and December 2010. Determinants were
baseline characteristics and treatment outcomes.
Study setting
Part of the former Soviet Union until 1991, Uzbekistan is a country in Central Asia with a pop-
ulation of more than 31 million [8]. It is made up of twelve provinces (oblasts), one autono-
mous republic (the Republic of Karakalpakstan) and the capital city, Tashkent.
TB control activities. TB control activities are coordinated countrywide by the Republi-
can Specialized Scientific-Practical Medical Center of Phthisiology and Pulmonology—essen-
tially the National Tuberculosis Programme (NTP). All patients diagnosed with TB are treated
free of charge within the NTP; there is no private sector for TB treatment. During the study
period all registered TB patients received treatment in accordance with the WHO recom-
mended DOTS strategy. At the province level, provincial TB hospitals provide TB control ser-
vices under the supervision of the Ministry of Health (MoH), province State Health
departments and the NTP.
After registration and initiation of treatment (category 1 treatment for new cases and cate-
gory 2 treatment for recurrent TB cases), patients are hospitalized during the intensive phase
of treatment (two months for new cases and three months for recurrent TB cases); thereafter
the continuation phase of treatment (four months for new patients and five months for recur-
rent cases) is provided on an ambulatory basis [2]. Patients undergo sputum smear testing
after treatment completion in the intensive phase and if the smears are negative for AFB
patients are referred to primary health care facilities for the continuation phase of treatment.
In certain situations (for example, a patient with smear negative pulmonary TB or a patient
with childhood TB), the patients may receive full ambulatory treatment from the beginning of
treatment. Treatment is prescribed by TB specialists during the intensive phase and by primary
health care workers during the continuation phase. The duration of both phases of treatment
may be extended based on sputum smear results.
At the time of the study, the country was covered by a network of TB laboratories that
included two National Reference Laboratories (NRL) (one in Tashkent and one at the Republi-
can TB dispensary in Nukus, Republic of Karakalpakstan), five bacteriological laboratories
(where only AFB microscopy and culture using solid media are done) and more than 300
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smear microscopy laboratories. None of these laboratories performed DNA fingerprinting of
Mycobacterium Tuberculosis strains.
TB treatment is provided by Provincial TB hospitals/dispensaries at the province level and
by TB dispensaries at both the district level (intensive phase) and the primary health care level
(continuation phase) for drug-sensitive and multidrug-resistant TB (MDR-TB—resistant to
both isoniazid and rifampicin). During the study, the Global Fund to Fight AIDS, Tuberculosis
and Malaria (GFATM) was supplying all first-line anti -TB drugs countrywide and second-line
drugs for pilot sites for the treatment of drug resistant tuberculosis (DR TB). Both drug-sus-
ceptible and drug-resistant TB patients are treated in accordance with the TB Order of the
Ministry of Health of the Republic of Uzbekistan, which aligns with WHO-recommended
guidelines [9].
NTP monitoring system. Since 2005, an Epi-Info based-TB-ESCM (Tuberculosis Elec-
tronic Surveillance and Case Management) system has been implemented countrywide for dis-
ease surveillance and case management. All diagnosed patients are individually recorded in
this register and all of their clinical data are recorded here. Standardized treatment outcomes
are monitored according to national and international recommendations.
Study population
The study included all new and recurrent TB patients in Uzbekistan registered within the NTP
and started on anti-TB treatment between January 2006 and December 2010.
Data sources, variables and data collection. The data source was the TB ESCM elec-
tronic register. Data variables included: TB registration number, socio-demographic charac-
teristics at the time of TB diagnosis (age, sex, place of residence, occupation etc.), clinical
characteristics at the start of TB treatment (TB type, category of TB—new and recurrent, and
co-morbidities) and treatment outcomes. Data pertaining to this study were exported into Epi-
Data (version 3.1, EpiData Association, Odense, Denmark).
Data analysis. Trends in recurrent TB were summarized using descriptive statistics. Base-
line socio-demographic and clinical characteristics of recurrent TB patients were compared
with new TB patients, and factors associated with recurrent TB determined by crude odds
ratios (ORs) and adjusted ORs. Adjusted ORs were determined through multivariate logistic
regression using a backward stepwise elimination approach until all remaining variables in the
model were significant at P = 0.05 or less. All related P-values were based on the Walds test
and 95% confidence intervals were used throughout. Data were analysed using EpiData Analy-
sis software (version 2.2.2.182, EpiData Association, Odense, Denmark), Stata/SE (version 12;
Stata Corporation, College Station, Texas 77845, USA) and Open Epi (Version 3.03a).
Ethics approval. Approval for this study was received from the National Ethics Commit-
tee under the Ministry of Health of Uzbekistan and from the Ethics Advisory Group of the
International Union Against Tuberculosis and Lung Disease, Paris, France. The study satisfied
the criteria for reports using routinely collected programmatic data set by the Me´decins Sans
Frontières Ethics Review Board (ERB), Geneva, Switzerland. During the analysis no patient
identifying information was used. As this was a retrospective analysis of programme routine
data, patient informed consent was not required.
Results
Trends in recurrent TB
Trends in recurrent TB cases are shown in Table 1. Between 2006 and 2008, the number of
recurrent cases per annum increased from 1530 to 2081 (3.4% increase), falling slightly
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between 2008 and 2010 (2081 to 1888 cases) but remaining stable as a proportion of all notified
cases during this period (9.4–9.9%).
Factors associated with recurrent TB
Based on the fact that our sample was extremely large (and there was therefore the need to bal-
ance statistical with clinical significance), an OR of 1.3 or more was used to single out factors
most associated with recurrent TB. These factors included being an older adult (36–55 years
old), having smear positive PTB, having particular co-morbidities (including chronic obstruc-
tive pulmonary disease (COPD) and HIV) and being unemployed, a pensioner or disabled
Table 2. In the case of geographical residence, residing in the Navoi mining area, the Republic
of Karakalpakstan, Bukhara province and the city of Tashkent was more strongly associated
with recurrent TB than residing in other provinces (based on the magnitude of the respective
ORs). Recurrent TB patients also had a higher likelihood of having an unfavourable treatment
outcomes (died, treatment failure or loss to follow-up) compared with new TB cases.
Due to concerns around the completeness of our data on co-morbidities, our multivariate
analysis exploring risk factors associated with recurrent TB compared with new TB, was also
run excluding the co-morbidity variable. This did not have any bearing on the specific factors
found to be associated with recurrent TB nor did it significantly affect the strength of these
associations.
Discussion
This is the first countrywide study from Uzbekistan to report on annual trends in recurrent TB
and associated risk factors. Despite a promising year-on-year decline in national TB notifica-
tions between 2006 and 2010, there has been an overall slight increase in the relative propor-
tion of recurrent TB for the same period from 6.5% to 9.9%. These findings, together with the
identification of possible risk factors associated with recurrent TB, raise a number of important
issues and highlight various areas where Uzbekistan needs to focus its TB control efforts.
Recent research carried out in Republic of Karakalpakstan found that, although three-quar-
ters of new cases were “successfully” treated, a third of these “successes” were later re-diag-
nosed with TB. Recurrence of TB was particularly common among patients whose initial
disease was multidrug resistant. Previous TB treatment was also associated with an increased
risk of disease recurrence [5].
While our study has indicated that the proportion of recurrent cases in Uzbekistan pla-
teaued at around 9% between 2008 and 2010, recent WHO country estimates suggest that this
Table 1. Trends in number of all notified tuberculosis cases and recurrent cases in Uzbekistan
between 2006 and 2010.
Year All notified cases of tuberculosis*
N
Recurrent cases
n (%)
2006 23534 1530 (6.5)
2007 22050 1904 (8.2)
2008 20990 2081 (9.9)
2009 20937 1955 (9.4)
2010 19869 1888 (9.6)
Total 107380 9358
* This includes all new cases and all retreatment cases (relapse, treatment after failure, return after loss to
follow-up and others).
https://doi.org/10.1371/journal.pone.0176473.t001
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Table 2. Association of socio-demographic and clinical characteristics of recurrent tuberculosis patients compared with all new tuberculosis
(TB) patients in Uzbekistan, 2006–2010.
Variables All new TB patients
n (%)
Relapse patients
n (%)
Crude OR
(95%CI)
Adjusted ORa
(95%CI)
P value
Total 81016 9358 - - -
Age (years)
Children (<15) 10875 (13) 212 (2) 0.2 (0.2–0.2) 0.8 (0.6–1.0) 0.05
Adolescent (15–18) 4095 (5) 252 (3) 0.5 (0.5–0.6) 0.9 (0.6–1.0) 0.07
Younger adults (19–35) 28884 (36) 3267 (35) 1 1
Older adults (36–55) 22423 (28) 3810 (41) 1.5 (1.4–1.6) 1.3 (1.2–1.4) <0.001
Elderly patients (>55) 14739 (18) 1817 (19) 1.1 (1.0–1.2) 1.0 (0.9–1.2) 0.59
Sex
Male 47345 (58) 5669 (61) 1.1 (1.0–1.1) 1.2 (1.1–1.2) <0.001
Female 33671 (42) 3689 (39) 1 1
Place of residence
Urban 25009 (31) 2939 (31) 1.2 (1.1–1.3)
Rural 55977 (69) 5491 (59) 1
Unknown 30 (<1) 928 (10) -
Provinces
Republic of Karakalpakstan 9669 (12) 2198 (23) 3.2 (2.9–3.5) 2.0 (1.8–2.3) <0.001
Tashkent city 5903 (7) 901 (10) 2.1 (1.9–2.4) 1.8 (1.6–2.1) <0.001
Andijan province 7041 (9) 719 (8) 1.4 (1.2–1.6) 1.1 (1.0–1.3) 0.04
Bukhara province 3563 (4) 454 (5) 1.8 (1.5–2.0) 1.9 (1.7–2.2) <0.001
Jizzakh province 3146 (4) 266 (3) 1.2 (1.0–1.4) 0.9 (0.8–1.1) 0.52
Kashkadarya province 7647 (9) 537 (6) 1 1
Navoi province 2804 (3) 319 (3) 1.6 (1.4–1.8) (0.9–1.2) 0.90
Namangan province 6995 (9) 709 (8) 1.4 (1.2–1.6) 1.4 (1.2–1.5) <0.001
Samarkand province 8082 (10) 936 (10) 1.6 (1.4–1.8) 1.4 (1.3–1.6) <0.001
Surkhandarya province 4203 (5) 154 (2) 0.5 (0.4–0.6) 0.5 (0.4–0.6) <0.001
Syrdarya province 1949 (2) 214 (2) 1.5 (1.3–1.8) 1.5 (1.3–1.8) <0.001
Tashkent province 7995 (10) 722 (8) 1.2 (1.1–1.4) 1.1 (1.0–1.2) 0.15
Fergana province 8056 (10) 758 (8) 1.3 (1.1–1.5) 1.2 (1.0–1.3) 0.001
Khorezm province 3771 (5) 438 (5) 1.6 (1.4–1.8) 1.2 (1.1–1.4) 0.003
Navoi mining company 184 (<1) 33 (<1) 2.5 (1.7–3.7) 4.9 (3.2–7.5) <0.001
Unknown 8 0 - - -
Co-morbiditiesb
None 65397 (81) 6404 (68) 1 1
Diabetes mellitus 2568 (3) 289 (3) 1.1 (1.0–1.3) 0.5 (0.5–0.6) <0.001
COPD 5398 (7) 826 (9) 1.6 (1.4–1.7) 1.2 (1.1–1.3) <0.001
Hypertension 2837 (4) 347 (4) 1.2 (1.1–1.4) 0.9 (0.8–1.0) 0.02
Stomach-duodenal ulcer 720 (<1) 71 (<1) 1.0 (0.8–1.3) 0.6 (0.5–0.8) <0.001
Psychological disorders 722 (<1) 57 (<1) 0.8 (0.6–1.1) 0.2 (0.1–0.3) <0.001
HIV 710 (<1) 103 (1) 1.5 (1.2–1.8) 1.5 (1.2–1.9) <0.001
Any oncological disease 146 (<1) 13 (<1) 0.9 (0.5–1.6) 0.4 (0.2–0.8) 0.008
Unknown 2518 (3) 1248 (13) - - -
TB type
PTB
Smear positive 24480 (30) 4483 (48) 1.6 (1.-1.7) 1.8 (1.7–1.9) <0.001
Smear negative 32240 (40) 3626 (39) 1 1
No sputum/sputum result 1940 (2) 370 (4) 1.7 (1.5–1.9) 1.9 (1.6–2.2) <0.001
(Continued )
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proportion has nearly doubled since then, being at around 17% in 2014 [1]. Restricted access
to programmatic data beyond 2010 precluded us from being able to examine more recent
trends in relapse TB. Not only is recurrent TB associated with worse treatment outcomes com-
pared with new TB [5, 10]—as noted in our study—but one of the major public health con-
cerns is the associated risk of drug-resistant TB, particularly MDR-TB. In the 2010 global
surveillance for drug-resistant TB, it was estimated that 7.9% of recurrent cases in the world
had MDR-TB [11]. In a country like Uzbekistan where rates of MDR-TB are among the high-
est in the world (23% among incident cases and 62% among retreatment cases [12]), tackling
what appears to be rising rates of recurrent TB, is thus of utmost importance.
Our study indicated a number of factors that seem to be associated with recurrent TB,
although in view of the substantial size of the study and the need to balance clinical and statisti-
cal significance, we have been selective in teasing out the factors that we deem to be important
clinically and from a public health perspective. First, the risk of recurrent TB was highest
among older adults (36–55 years). Unaware of any previous studies that have identified partic-
ular age groups as being more at risk of recurrent TB, we postulate that this finding is likely
linked to other co-determinants such as poor treatment adherence, smoking [13], alcohol
Table 2. (Continued)
Variables All new TB patients
n (%)
Relapse patients
n (%)
Crude OR
(95%CI)
Adjusted ORa
(95%CI)
P value
EPTB 22356 (28) 879 (9) 0.3 (0.3–0.4) 0.6 (0.5–0.6) <0.001
History of contact with TB patient
No 75457 (93) 6630 (71) 1.1 (1.0–1.3)
Yes 4810 (6) 361 (4) 1
Unknown 749 (<1) 2367 (25) -
History of imprisonment d
No 36663 (45) 3128 (33) 1
Yes 368 (<1) 57 (<1) 1.8 (1.4–2.4)
Unknown 43985 (54) 6173 (66) -
Occupational status
Worker 10908 (13) 568 (6) 1 1
Pupil/student 10661 (13) 208 (2) 0.4 (0.3–0.4) 0.8 (0.6–1.0) 0.04
Handicapped 3052 (4) 1274 (14) 8.0 (7.2–8.9) 10.0 (8.9–11.2) <0.001
Pre-school age 2938 (4) 21 (<1) 0.1 (0.1–0.2) 0.3 (0.2–0.5) <0.001
Pensioner 11602 (14) 1081 (12) 1.8 (1.6–2.0) 2.1 (1.8–2.4) <0.001
Jobless 39283 (48) 4200 (45) 2.1 (1.9–2.2) 2.1 (1.9–2.3) <0.001
Unknown 2572 (3) 2006 (21) - - -
Treatment outcomes
Treatment success 70445 (87) 6810 (73) 1
Died 3493 (4) 936 (10) 2.8 (2.6–3.0) <0.001
Failure 1858 (2) 480 (5) 2.7 (2.4–3.0) <0.001
Loss to follow up 4162 (5) 841 (9) 2.1 (1.9–2.3) <0.001
Transferred out 1058 (1) 291 (3) 2.8 (2.5–3.2) <0.001
COPD, Chronic Obstructive Pulmonary Disease; PTB, Pulmonary TB; EPTB, Extrapulmonary TB; OR, Odds Ratio, CI, Confidence Interval
a Adjusted odds ratios only presented for variables included in the multivariate model; 84389 records included in the multivariate model due to missing
records for some variables
b Co-morbidities are generally self-reported by patients, and only one co-morbidity per patient can be reported in the electronic reporting system
d History of imprisonment not included in the multivariate model due to large amounts of unknown data
https://doi.org/10.1371/journal.pone.0176473.t002
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intake and co-existing morbidities—factors that we were unable to assess and control for in
this study. Further investigation would be needed to establish these reasons so that more tar-
geted measures aimed at mitigating these factors could be implemented.
Second, the risk of recurrent TB was higher in certain parts of the country, in particular in
the Navoi mining company. This particular finding may be related to an increased incidence
of silicosis among miners (linked to the presence of silica dust in the mines), and silicosis has
been shown to be a risk factor for TB [14].
In other parts of the country we can only speculate, but the geographic disparities may
reflect several issues, like: i) variations in drug resistance prevalence and resistance patterns
(the highest rates of MDR-TB have been reported in the Republic of Karakalpakstan for exam-
ple [12]), ii) differences in the performance of local TB control activities and local primary
health care services, iii) the availability of first and second line anti TB drugs in the open mar-
ket, and/or iv) differences in patient characteristics (e.g. socio-economic status, tobacco use,
alcohol consumption, population movement and migration) [15, 16]. Operational research at
the level of the province, including qualitative research methods, may help to identify these
specific factors.
Third, certain co-morbidities were found to be associated with an increased risk of recur-
rent TB, including HIV and COPD. HIV is well known to increase the risk of recurrent TB
both in high and low TB burden settings, [7, 17–19], although reinfection rather than true
relapse is reported to be more common among HIV-infected individuals than non-infected
persons [20]. Uzbekistan has a low HIV prevalence (0.2%) and therefore HIV is unlikely to be
a major contributor of recurrent TB overall [21, 22]. However, the HIV epidemic in Uzbeki-
stan is far from abating and high risk groups for HIV (in particular injecting drug users, sex
workers and prisoners) [23] might be ‘hot spots’ for recurrent TB. COPD was also found to be
associated with recurrent TB, corroborating the findings from other studies [24, 25]. COPD
may increase the risk of recurrent TB because of fibrotic changes in the lung and reduced anti-
TB drug penetration into the lung tissue [26]; evidence also suggests that high dose oral corti-
costeroids and oral β-agonist medications used for COPD may weaken the essential defense
mechanism against M. tuberculosis in the airway and lung parenchyma [27]. Further study is
nonetheless needed to better understand the link between COPD and recurrent TB.
Surprisingly, diabetes mellitus (DM) was not found to be associated with an increased risk
of recurrent TB, in fact the converse was found: DM was found to be associated with a lower
risk of recurrent TB. This is counter to substantial evidence showing that DM increases the
risk of TB and also recurrent TB [28]. We suspect that this is a reflection of the incompleteness
of our data on DM, primarily linked to two factors: i) first the electronic reporting system used
in Uzbekistan only allows one co-morbidity per patient to be reported, despite the fact that
patients may of course have more than one important co-morbidity. As such, some patients
with known DM may not be reported as having this condition; ii) co-morbidities are generally
self-reported by patients and given that half of the DM cases worldwide do not know that they
have DM, it may go unidentified and thus unreported for TB patients.
Fourth, being disabled, a pensioner or unemployed was associated with an increased risk of
recurrent TB, particularly being disabled. Once again, we can only speculate but we suspect
that this is probably linked to patient-related characteristics (e.g. pre-existing co-morbidities,
poor access to anti-TB drugs, poor treatment adherence) [29].
Finally, having smear positive pulmonary TB was associated with a high risk of recurrent
TB compared with having smear negative pulmonary TB or extrapulmonary TB, mirroring
the findings from other studies [5] and showing a similar situation to that seen in other
central Asian countries [1]. Smear-positive TB at baseline was associated with recurrent TB—
unfortunately we do not have robust data for the question about smear-positive TB after the
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intensive phase of treatment and therefore cannot comment here on the association with
recurrent TB
One question that our data was not able to answer was whether recurrent TB cases were
relapse TB or caused by exogenous reinfection. Evidence suggests that in countries with a low
TB burden, TB recurrence is usually caused by relapse [30], whereas in countries with a high
TB burden the principle cause is reinfection [31], especially when high levels of HIV infection
co-exist [20]. In countries with a medium TB burden (like Uzbekistan), relapse and reinfection
are both thought to play a role [32], with their relative contribution depending on the preva-
lence of epidemiological risk factors and the microbiological features of circulating M. tubercu-
losis strains. Relapse TB tends to reflect inadequacies in clinical management (linked to drug
resistance, poor treatment adherence, poor drug quality, or inadequate treatment regimens for
instance); while reinfection is often a result of a high prevalence of infectious TB in the com-
munity, low levels of immunity among individuals having completed TB treatment, HIV infec-
tion, or specific characteristics of circulating M. tuberculosis strains [5,12]. Further
investigation would be needed to ascertain the relative contribution of relapse TB and reinfec-
tion to recurrent TB in Uzbekistan, together with the specific reasons. At any rate, given what
appears to be a parallel rise in recurrent TB and MDR-TB in the country, we strongly suspect
that MDR-TB has a large part to play in recurrent TB (true relapse and reinfection).
The main strength of this study was that it was a countrywide study and therefore nationally
representative. Performing a risk factor analysis at the national level was also made possible by
the fact that Uzbekistan has implemented a TB surveillance system that captures individual
patient-level data, rather than aggregate data as in many other national TB programmes.
There were several study limitations. First, the study relied on routinely collected data
which may have been subject to incompleteness or inaccurate capture. Indeed, substantial
amounts of data were incomplete for certain variables such as ‘history of imprisonment’,
restricting our ability to assess the association of such factors with recurrent TB. Second, this
evaluation was limited to the available data in Uzbekistan’s national TB surveillance system
and as such data on factors such as smoking, alcohol and injecting drug use were not routinely
recorded. Third, the study design that we used did not involve the follow-up of ‘successfully
treated’ patients to ascertain who and who did not develop recurrent disease; in Uzbekistan TB
patients presenting for repeat episodes of treatment are not given the same unique identifier
each time and therefore their treatment history cannot be accurately tracked in the electronic
register. Instead, we compared new TB cases with recurrent cases in terms of associated fac-
tors, the limitation with this design being that a proportion of the new cases will have subse-
quently developed recurrent TB (i.e. their risk profile might be no different from a registered
recurrent case). In this way, our study likely underestimated the strength of association of
identified risk factors with recurrent TB. It also precluded any assessment of how long after
“successful treatment”, patients develop recurrent TB. Finally, restricted access to data unfor-
tunately precluded us from being able to examine national trends in recurrent rates of TB in
Uzbekistan up until the current time. Reference to recent WHO estimates was thus our only
means of gauging how the situation seems to have progressed since 2010.
The findings of our study have a number of implications. First, given the association
between HIV and recurrent TB, ensuring that all TB patients are routinely screened for HIV as
per the national guidelines in Uzbekistan is important. In addition, HIV co-infected TB
patients not already on antiretroviral treatment (ART) should be started on ART as soon as
possible after starting anti-TB treatment, together with co-trimoxazole preventive therapy.
Both interventions are known to reduce recurrent TB [33–35]. Second, among COPD patients
that have a history of previous TB, regular monitoring for the development of pulmonary TB
seems prudent, especially among those receiving high doses of oral corticosteroids. Third, data
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capture on co-morbidities needs to be revised in the national TB electronic register so that
multiple co-morbidities per patient can be simultaneously captured. Such data are important
for understanding the relationship between different co-morbidities and TB, and for devising
more effective responses to deal with inter-related burdens of diseases. Finally, given what
seem to be rising rates of recurrent TB in Uzbekistan, reliance on end-of-treatment outcomes
to judge the potential effectiveness of DOTS in controlling TB may no longer be appropriate.
Instead, implementing and expanding the case management of drug resistant TB might be a
plausible consideration [36].
In conclusion, this study shows that despite signs of declining national TB notifications
between 2006 and 2010, the relative proportion of recurrent TB cases appears to be climbing.
These findings, together with the identification of possible risk factors associated with recur-
rent TB, highlight various areas where Uzbekistan needs to focus its TB control efforts, partic-
ularly in light of the country’s rapidly emerging MDR-TB epidemic.
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